Differential Tumor Expression of Inhibitor of Differentiation-1 in Prostate Cancer Patients With Extreme Clinical Phenotypes and Prognostic Implications
| Autor: | Alfonso Calvo, David Rosell, Inés López, Angel Panizo-Santos, Mariano Ponz-Sarvise, Ignacio Gil-Bazo, Isabel Gil-Aldea, Eduardo Castanon, Miriam Redrado, Paul Nguewa |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Inhibitor of Differentiation Protein 1
Male PCA3 Oncology medicine.medical_specialty Urology medicine.medical_treatment Gene Expression Kaplan-Meier Estimate Adenocarcinoma Disease-Free Survival Prostate cancer Antigen Internal medicine medicine Humans RNA Messenger Aged Proportional Hazards Models Retrospective Studies business.industry Prostatectomy Hazard ratio Prostatic Neoplasms Cancer Middle Aged Prognosis medicine.disease Phenotype Cohort Immunohistochemistry business |
| Zdroj: | Clinical Genitourinary Cancer. 12:87-93 |
| ISSN: | 1558-7673 |
| Popis: | Background In the prostate-specific antigen era, potentially indolent prostate tumors are radically treated, causing overtreatment. Molecular prognostic factors might differentiate indolent from aggressive tumors, allowing avoidance of unnecessary treatment. Patients and Methods Fifty-two prostate cancer patients (20 organ-confined and 32 metastatic) were selected. All formalin-fixed and paraffin-embedded primary biopsies and matched metastases of 15 of them were evaluated for tumor and endothelial cell Id1 protein expression. Seventy-nine additional patients with organ-confined prostate cancer were selected for Id1 mRNA in silico analysis. Results Among metastatic cancer subjects, 48% of primary tumors and 38% of metastases showed Id1 tumor cell expression, and 79% of primary tumors and 81% of metastases showed endothelial immunoreactivity. In the organ-confined group none of them showed Id1 protein tumor cell expression and 50% displayed endothelial expression. In the metastatic patients group, lower levels of Id1 protein predicted a nonsignificant longer overall survival (13 months vs. 7 months; P = .79). In the in silico analysis, however, lower levels of Id1 mRNA predicted a longer disease-free survival (61 months vs. not-reached; P = .018) and the hazard ratio for progression was 0.451 ( P = .022) in favor of patients showing lower levels. Conclusion In our cohort, it seems to be a differential epithelial expression of Id1 protein according to the prognostic features (metastatic/poor prognosis vs. organ-confined/good prognosis). In localized tumors treated with radical prostatectomy, higher Id1 mRNA expression levels might predict a higher hazard ratio for progression and a shorter disease-free survival. Further validation of these results in larger prospective series is warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect